Determinants of hypertension-related cardiac organ damage: Beyond the haemodynamic overload

Journal of Hypertension

Volumn 23, Issue 5, 2005, Pages 941-943

  Grassi, Guido ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN;

ADRENERGIC SYSTEM; EDITORIAL; ELECTROCARDIOGRAM; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 18344390655     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000166833.25194.7b     Document Type: Editorial

References (27)

1. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984; 2:581-587.
2. Reid IA. Interaction between angiotensin II, sympathetic nervous system and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262:E763-E778.
3. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for neural regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management. New York, New York: Raven Press; 1995, pp. 1763-1795.
4. Mancia G, Saino A, Grassi G. Interactions between the sympathetic nervous system and the renin-angiotensin system. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management. New York, New York: Raven Press; 1995, pp. 399-407.
5. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823.
6. Swedberg K, Eneroth P, Kjekshus J, Wilhelsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group. Circulation 1990; 82:1730-1736.
7. Omland T, Aarsland T, Aakvaag A, Lie RT, Dickstein K. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol 1993; 72:255-259.
8. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute tromboembolic stroke. Neurology 2001; 57:833-838.
9. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482-487.
10. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:2230-2234.
11. Schlaich MP, Kaye DM, Lambert E, Hastings J, Lambert G, Esler MD. Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens 2005; 23:1077-1082.
12. Levy D, Andersen KM, Savage DD, Kannel WB, Christiansen LC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Int Med 1988; 108:7-13.
13. Kannel WB, Gordon T, Offit D. Left ventricular hypertrophy by EKG. Prevalence, incidence and mortality in the Framingham Study. Ann Int Med 1969; 71:89-105.
14. Casale PN, Devereux RB, Milver M. Value of echocardiography measurement in predicting cardiovascular morbid events in hypertensive men. Ann Int Med 1986; 105:173-178.
15. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
16. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343-2349.
17. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment in hypertension. JAMA 2004; 292:2350-2356.
18. Devereux RB. Hypertensive cardiac hypertrophy. Pathophysiologic and clinical characteristics. Hypertension: Pathophysiology and Management. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management. New York, New York: Raven Press; 1990, pp. 359-377.
19. Tarazi RC, Sen S, Saragoca M, Khairallah P. The multifactorial role of catecholamines in hypertensive cardiac hypertrophy. Eur Heart J 1982; 3:103-110.
20. Laks MM, Morady F, Swan HJ. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 1973; 64:75-78.
21. Zierhut W, Zimmer HG. Significance of myocardial-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res 1989; 65: 1417-1425.
22. Patel MB, Stewart JM, Loud AV, Anversa P, Wang J, Fiegel L, Hintze TH. Altered function and structure in the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991; 84:2091-2100.
23. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31:68-72.
24. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous S, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565.
25. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 28(105):2512-2517.
26. Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlof B, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004; 110:552-557.
27. Grassi G, Seravalle G, Quarti Trevano F, Dell'Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 2003; 42:870-872.